title: The epidermal growth factor receptor (EGRF) in lung cancer.
abstract: In the last decade, important advances have been made in understanding of cancer biology, particularly non-small-cell lung cancer (NSCLC) with the discovery of oncogenic drivers of the disease. The epidermal growth factor receptor (EGFR) gene and its pathways was the first oncogenic driver discovered to be mutated and treatable in lung cancer. Treatment with EGFR tyrosine kinase inhibitors (TKIs) is the standard of care for molecularly selected EGFR-mutant patients, while its role in unselected lung cancer patients is nowadays controversial. This review will provide an overview of the EGFR pathway and options for its treatment of lung cancer.
authors: Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Universitat Autónoma de Barcelona, Department of Medicine, Badalona, Barcelona Spain.
authors: Enric
authors: E
authors: Carcereny
authors: Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Universitat Autónoma de Barcelona, Department of Medicine, Badalona, Barcelona Spain.
authors: Teresa
authors: T
authors: Morán
authors: Hospital Santa Tecla, Tarragona, Spain.
authors: Laia
authors: L
authors: Capdevila
authors: Hospital de Granollers, Barcelona, Spain.
authors: Sara
authors: S
authors: Cros
authors: Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Universitat Autónoma de Barcelona, Department of Medicine, Badalona, Barcelona Spain.
authors: Laia
authors: L
authors: Vilà
authors: Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Universitat Autónoma de Barcelona, Department of Medicine, Badalona, Barcelona Spain.
authors: Maria
authors: M
authors: de Los Llanos Gil
authors: Hospital de Mataró, Barcelona, Spain.
authors: Jordi
authors: J
authors: Remón
authors: Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Universitat Autónoma de Barcelona, Department of Medicine, Badalona, Barcelona Spain ; Cancer Biology & Precision Medicine Program, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Badalona, Barcelona Spain ; Fundación Molecular Oncology Research, Sabino Arana 5-19, Barcelona, Spain.
authors: Rafael
authors: R
authors: Rosell
keywords: EGFR; Epidermal growth factor receptor; Lung cancer; TKI; Tyrosine kinase inhibitors